Peter Rouvelas, MD
Interventional Cardiology · Brooklyn, NYNPI 1245243609
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $290,001 of the $332,291 with a category attached, or 87.3%. Novo Nordisk accounts for 62.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $113,089 and has fallen 68.3% since, to $35,797 in 2025. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $758.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$207K
- Johnson & Johnson$86K
- Amarin Pharma, Inc.$27K
- Edwards Lifesciences$7K
- Abbott$1K
- Amgen$524
- plus $3K from 17 others
What the payments were for
- Consulting fees$16,6355%
- Speaking & faculty fees$290,00187%
- Travel & lodging$14,6484%
- Food & beverage$11,0073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 126 | $206,648 |
| Johnson & Johnson | 104 | $86,419 |
| Amarin Pharma, Inc. | 36 | $27,008 |
| Edwards Lifesciences | 13 | $7,484 |
| Abbott | 14 | $1,443 |
| Amgen(2 entities) | 21 | $524 |
| Sanofi-aventis U.S. LLC | 21 | $487 |
| Novartis | 21 | $396 |
| AstraZeneca | 17 | $392 |
| GSK | 17 | $373 |
| Alnylam Pharmaceuticals Inc. | 9 | $235 |
| Pfizer | 8 | $171 |
| Actelion Pharmaceuticals US, Inc. | 7 | $164 |
| Boehringer Ingelheim | 6 | $160 |
| Merck | 5 | $114 |
| Boston Scientific | 3 | $84 |
| Biotronik Inc. | 2 | $48 |
| Lilly USA, LLC | 3 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$163,905
- XARELTO$85,227
- Vascepa$26,561
- RYBELSUS$17,551
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$7,125
- Confirm Rx$1,088
- SAPIEN 3 Ultra RESILIA$127
How this compares
$332,291 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 176 | $160,500 |
| JardianceEmpagliflozin | 109 | $116,582 |
| EntrestoSacubitril/Valsartan | 98 | $101,458 |
| EliquisApixaban | 88 | $94,941 |
| OzempicSemaglutide | 81 | $84,912 |
| FarxigaDapagliflozin Propanediol | 60 | $59,843 |
| TradjentaLinagliptin | 37 | $42,138 |
| TrulicityDulaglutide | 20 | $39,647 |
| VascepaIcosapent Ethyl | 87 | $39,371 |
| JanuviaSitagliptin Phosphate | 24 | $26,050 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,600 |
| ProliaDenosumab | 13 | $22,171 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $20,926 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $20,901 |
| Repatha SureclickEvolocumab | 23 | $17,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $86,419 | $160,500176 claims |
| Boehringer IngelheimJardiance, Tradjenta | $160 | $158,720146 claims |
| NovartisEntresto | $396 | $101,45898 claims |
| PfizerEliquis | $171 | $94,94188 claims |
| Novo NordiskOzempic | $206,648 | $84,91281 claims |
| AstraZenecaFarxiga | $392 | $59,84360 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $47 | $54,37034 claims |
| MerckJanuvia, Janumet | $114 | $46,97637 claims |
| GSKTrelegy Ellipta | $373 | $23,60030 claims |
| AmgenProlia | $524 | $22,17113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Brooklyn
- Sorin BrenerBrooklyn$166K
- Justin RatcliffeBrooklyn$137K
- Robert FrankelBrooklyn$59K
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.